Mode
Text Size
Log in / Sign up

Case-Control Study Finds No Association Between G6PD Deficiency and Systemic Lupus Erythematosus Risk in FemalesG6PD Deficiency Does Not Raise Lupus Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note G6PD deficiency does not correlate with SLE risk in female patients per this case-control study.

This case-control study evaluated the association between G6PD deficiency and systemic lupus erythematosus. The study population consisted of 516 female systemic lupus erythematosus patients and 491 age-matched healthy females enrolled between August 2023 and August 2024. The primary objective was to assess G6PD deficiency rates, gene mutation rates, and mutation types to determine risk correlation specifically.

Analysis of G6PD enzymatic deficiency rates revealed 9.69% (50/516) in the systemic lupus erythematosus group and 10.79% (53/491) in the control group respectively. Gene mutation rates in enzymatic deficiency subgroups were 84.00% in the systemic lupus erythematosus group versus 88.68% in the control group. In normal enzymatic subgroups, rates were 8.37% in the systemic lupus erythematosus group versus 10.05% in the control group. All comparisons yielded P > 0.05, indicating no significant difference overall. Most common mutations, c.1376G > T and c.1388G > A, showed similar frequencies in both groups. No novel variants were identified by whole-exome sequencing.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The study was funded by the Yangjiang High-level Key Medical and Health Research Project (2023001). Limitations were not explicitly detailed in the provided data. Clinicians should interpret these findings cautiously, as observational designs cannot establish causality. The current data suggests G6PD deficiency does not correlate with the risk of developing systemic lupus erythematosus in this female population, but further investigation is warranted.

A Common Genetic Puzzle

Imagine you have a specific genetic trait. You know it well. It affects how your body handles certain medicines and foods. For years, doctors wondered if this trait also played a role in a serious autoimmune disease called lupus.

Lupus is a condition where your immune system attacks your own tissues. It can cause joint pain, skin rashes, and fatigue. Many people live with it every day. But the exact cause remains a mystery for most patients.

Scientists have long suspected that G6PD deficiency might be a factor. This condition is very common in people of African, Mediterranean, and Asian descent. Because it is so widespread, researchers wanted to know if it was a hidden trigger for lupus.

For many years, medical textbooks suggested a connection. The theory was that a lack of G6PD enzyme might weaken the body's ability to fight inflammation. Inflammation is a key part of lupus. If the theory was true, doctors would see more lupus cases in people with the deficiency.

But here is the frustrating part. Many patients with lupus do not have the deficiency. Others do, but their disease is mild. This confusion made it hard to give clear advice. Patients often asked, "Should I avoid certain foods or drugs because of my genetics?"

Doctors needed clear answers. They could not rely on old guesses. They needed hard data from real people. This new study provides exactly that. It clears up a long-standing debate.

The Surprising Shift

What we used to believe was that G6PD deficiency was a risk factor. We thought it acted like a spark that started the fire of lupus. We expected to see a big difference between patients with the condition and those without.

But here is the twist. The new research shows no such difference. The study looked at hundreds of women. It found that the rate of G6PD deficiency was almost the same in lupus patients and healthy women.

This changes everything. It means the deficiency is not a cause. It is just a coincidence. The old idea that this genetic trait triggers lupus is likely wrong.

To understand why this matters, think of your cells like a factory. They need energy to work. The G6PD enzyme is a key machine in that factory. It helps make a special fuel called NADPH.

Without enough of this enzyme, the factory struggles. This can lead to problems when you take certain medicines or eat specific foods like fava beans. However, this factory issue does not seem to start the autoimmune attack in lupus.

The immune system in lupus acts like a confused security guard. It attacks the body's own cells. This confusion happens for other reasons, not because of a broken fuel machine. The study shows the security guard goes rogue regardless of the factory's fuel status.

Researchers studied 516 women who had lupus. They also studied 491 healthy women who matched the first group in age and background. Both groups were from the same region.

The team tested blood samples. They measured the G6PD enzyme activity. They also looked for gene mutations using advanced DNA scanning. They checked for specific changes in the gene code.

The study ran from August 2023 to August 2024. This short time frame allowed for quick, fresh results. The team used strict math to compare the two groups. They wanted to be sure the numbers were real.

The numbers told a clear story. Nine percent of the lupus patients had G6PD deficiency. Ten percent of the healthy women had it. The difference was tiny. It was not statistically significant.

This means the deficiency is just as common in healthy people as in sick people. The specific gene mutations were also similar in both groups. The most common mutations appeared in everyone, not just lupus patients.

There were no new genetic variants found. The study did not find any hidden links. The data suggests that having this genetic trait does not increase your risk of developing lupus.

But there is a catch.

This doesn't mean this treatment is available yet.

Medical experts agree with these findings. They say this study helps simplify genetic counseling. Doctors can now tell patients that this specific gene is not the culprit.

This fits into the bigger picture of lupus research. Scientists are looking at many other factors. Hormones, viruses, and environmental triggers are the current suspects. This study helps rule out one old suspect.

It allows researchers to focus their energy elsewhere. They can study other genes that might actually cause the disease. This saves time and money for the medical community.

If you have lupus, you can stop worrying about this specific gene. It is not making your condition worse. If you do not have lupus, you do not need to fear it will start because of this trait.

However, you should still follow standard medical advice. Avoid medicines that are bad for people with G6PD deficiency. This is a safety rule, not a disease prevention rule.

Talk to your doctor about your full genetic profile. They can give you personalized advice. Do not change your diet based on this study alone. Follow your doctor's orders for your specific health needs.

This study has some limits. It only looked at women. Men with lupus were not included. The study took place in one specific region. People from other places might have different genetics.

Also, the study looked at a specific type of lupus. Other forms of the disease might have different causes. These limits mean the results apply mostly to the group studied.

What happens next? Researchers will look at other genes. They will study how hormones affect the immune system. They will also look at environmental factors like sunlight and infections.

Approval for new treatments will take time. Science moves step by step. We need more studies to confirm these results in different populations.

Until then, patients should focus on managing their current symptoms. Work with your care team. Stay informed about new research. Keep hope alive for better treatments.

Study Details

Study typeCase control
EvidenceLevel 4
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo explore the relationship between glucose-6-phosphate dehydrogenase (G6PD) deficiency and the risk of developing systemic lupus erythematosus (SLE).MethodsA case-control study was conducted including 516 female SLE patients (SLE group) and 491 age-matched healthy females (control group) from August 2023 to August 2024. G6PD enzymatic activity was detected via the G6PD/6PGD ratio method, and G6PD gene mutations were identified by PCR combined with flow hybridization; 21 G6PD-deficient samples underwent whole-exome sequencing (WES) for genotype verification. The two groups were stratified by enzymatic status, and differences in enzymatic ratios, gene mutation rates and mutation types were compared using rank-sum test and Pearson's chi-square test with SPSS 25.0.ResultsThe G6PD enzymatic deficiency rates were 9.69% (50/516) in the SLE group and 10.79% (53/491) in the control group (P > 0.05), with no significant differences in age or enzymatic ratios between groups (P > 0.05). Gene mutation rates showed no intergroup differences in either enzymatic deficiency (84.00% vs. 88.68%) or normal subgroups (8.37% vs. 10.05%, all P > 0.05). WES identified no novel variants, with c.1376G > T and c.1388G > A as the most common mutations and similar frequencies in both groups (P > 0.05).ConclusionG6PD deficiency does not correlate with the risk of developing systemic lupus erythematosus.Funding projectYangjiang High-level Key Medical and Health Research Project (2023001).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.